PolitiKit

Consultant In effect since Jun 19, 2025

Consultant Anastasios Housakos of Wellington Advocacy

Consultant lobbyists

• Anastasios Housakos Former public office holder

  Formerly Research Advisor, House of Commons, Opposition Leader’s Office (2020–2021)

  Formerly Policy Intern, House of Commons, Opposition Leader’s Office (2019–2019)

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Environment and Climate Change Canada (ECCC), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (16)Hide details

• Free trade treaty agreement as they relate to The Canada-United States-Mexico Agreement (CUSMA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
• Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
• Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
• Proposed pharmacare legislation related to any future national pharmacare program
• Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
• Scientific Research and Experimental Development (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
• Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
• Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
• Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
• Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
• Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
• Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
• Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
• Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
• Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
• Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products

Registration 953835-381436-1. Look it up in the official Registry